A Phase II Trial of TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer

Trial Profile

A Phase II Trial of TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs Durvalumab (Primary) ; TPIV 200 (Primary)
  • Indications Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Nov 2017 According to a TapImmune media release, interim results (n = 27) from this trial are expected in 1H 2018.
    • 31 Aug 2017 According to a TapImmune media release, the company will resume the enrollment and expects to study to be completed as planned in 2018 if the safety profile remains favorable and there are sufficient signs of tumor response.
    • 31 May 2017 According to a TapImmune media release, interim results from this trial are expected in 3Q 2017. To date, 27 patients have been enrolled in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top